Patient P-02475

Synthetic patientMETA-24 · Day 115 · 45–54 · F · baseline S11Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Improving

Nutritional resilience

Declining

Discontinuation risk

19%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S11

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days

Toxicity-13
Treatment adherence+10
GI instability+6
Inflammatory activity-6
Nutritional resilience-6

What helped?

No interventions yet.

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

36 min

stable · +0.9 vs previous 14 d

Sleep duration

Wearable

7.5 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

5.6/10

stable · +0.0 vs previous 14 d

Steps

Wearable

3,706

improving · +283 vs previous 14 d

GI burden

Companion

18.4/100

improving · -4.5 vs previous 14 d

Adherence

Companion

100 %

stable · +3.4 vs previous 14 d

Sleep quality

Wearable

53.3/100

improving · +3.1 vs previous 14 d

Glucose, CGM daily mean

CGM

120 mg/dL

stable · -2.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 78 from the failing basin, 19 from restoration.

Would help

No untried action with strong evidence. Compose one from primitives.
More protein
GI -2.8 next day on high-intake days · n 21

Would not help

Nothing clearly counter-productive in the record.

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-2.8supporter · 95%
Ultra-processed food
+1.2no signal · 39%
Histamine load
-0.9no signal · 28%
Caffeine
+0.9no signal · 30%
Alcohol
+0.7no signal · 25%
Insoluble fibre
+0.6no signal · 17%
Dietary fat load
+0.4no signal · 15%
Simple carbohydrates
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 31 ms, trending down
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
Autonomic recovery ↓20
- Wearable3,706 steps/day

DNA

Fictional pharmacogenomic panel

CYP2D6 Intermediate metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 4.3 · butyrate capacity 67/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 30 ms
Sleep: 7.8 h
Steps: 3,713
Resting HR: 69 bpm

Daily log: GI score 18, nutritional resilience 62, adherence 100.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02518	51%	S17	DT-01	improved	68
P-02462	45%	S12	DT-01	improved	65
P-02620	42%	S01	HY-01	improved	64
P-02064	41%	S04	SC-12	improved	57
P-02126	40%	S16	DT-01	improved	59
P-02150	40%	S11	HY-01	improved	45
P-02235	40%	S14	DT-01	improved	50
P-02354	40%	S01	CR-01	improved	78
P-02538	40%	S02	GI-04	improved	59
P-02082	39%	S12	NP-02	improved	53
P-02698	39%	S06	ME-01	improved	71
P-02033	38%	S06	GI-04	improved	51